Darunavir for Use in Pregnant Women with HIV. - Wikidata - wikimedia - TriplyDB

Darunavir for Use in Pregnant Women with HIV.

Darunavir for Use in Pregnant Women with HIV.

http://www.wikidata.org/entity/Q41922010

about

Darunavir for Use in Pregnant Women with HIV.

http://www.wikidata.org/entity/Q41922010

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Darunavir for Use in Pregnant Women with HIV.

@en

type

label

Darunavir for Use in Pregnant Women with HIV.

@en

prefLabel

Darunavir for Use in Pregnant Women with HIV.

@en

P1433

Q41922010-14695654-5B06-4735-BDBD-369796B76ED4

P1476

Q41922010-6BF2D5BF-00B7-4EE2-8033-690F40D21444

P2093

Q41922010-B30DE7AD-3A14-49A9-AC00-E9A64E9B8A15

Q41922010-D03441A8-A313-4CA6-B5A9-35A35F8008D9

P2860

Q41922010-0A810DCF-4C4B-4151-81E0-68247E1E45B9

Q41922010-1354788B-C79E-4481-973A-13543303346B

Q41922010-14C0ABC3-F8C4-49E4-A503-6E1C47B6A07D

Q41922010-2E39F1F1-A192-48E5-AECB-009E82319BBB

Q41922010-2ED80359-43FD-491A-94B6-C3C23A0D8003

Q41922010-2F67E9FB-E72C-4D3D-8F94-324B60D1828E

Q41922010-440EF03B-518C-4796-9736-5EE16DC558F2

Q41922010-462E6806-63BF-4C5C-BCFE-7269DCACB73E

Q41922010-4769329E-95F8-45B4-BD7C-AFDC47B00FCD

Q41922010-4B3FE1CC-0C72-4C24-B488-52FA080F0712

P31

Q41922010-84E42121-3C6B-4081-BB4C-5EE589F5EC55

P356

Q41922010-DAAB1036-7021-4D95-80B5-CB41E2E2095B

P407

Q41922010-9A1C09BF-36BC-42C4-BD5E-F218E275DC25

P577

Q41922010-E8DD4215-AFE2-4AED-BB60-55755D471DBA

P698

Q41922010-B713532C-2FAA-465D-9C38-31F3FBA3A965

P356

17512433.2017.1390428

P1433

Expert Review of Clinical Pharmacology

P1476

Darunavir for Use in Pregnant Women with HIV.

@en

P2093

Angela Kashuba

http://www.w3.org/2001/XMLSchema#string

Robert Pope

http://www.w3.org/2001/XMLSchema#string

P2860

The contribution of HIV to pregnancy-related mortality: a systematic review and meta-analysis

Is protease inhibitors based antiretroviral therapy during pregnancy associated with an increased risk of preterm birth? Systematic review and a meta-analysis

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

Reduction of maternal mortality with highly active antiretroviral therapy in a large cohort of HIV-infected pregnant women in Malawi and Mozambique

Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice.

Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis.

Effect of HIV infection on pregnancy-related mortality in sub-Saharan Africa: secondary analyses of pooled community-based data from the network for Analysing Longitudinal Population-based HIV/AIDS data on Africa (ALPHA).

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.

Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post-partum: results of the BAN Study.

Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy.

P31

scholarly article

P356

10.1080/17512433.2017.1390428

http://www.w3.org/2001/XMLSchema#string

P407

P577

2017-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28988509

http://www.w3.org/2001/XMLSchema#string